Benlysta (Belimumab), a new treatment for systemic lupus erythematosus by GSK, can be listed on the ‘Pharmaceutical Benefit List and Upper Limit Price List’ in February next year as soon as the administrative procedures are carried out sequentially.

According to the pharmaceutical industry on the 28th, the government will promote insurance benefits for Benlysta 120mg and Benlysta 400mg.

Benlysta is an injection approved by the MFDS for “the treatment of adult patients with autoantibody-positive active systemic lupus erythematosus being treated with standard therapy.” The number of domestic patients subject is about 835.

In June 2013, after obtaining the approval of the